Micrometastases: marker of metastatic potential or evidence of residual disease?

G C O'Sullivan, J K Collins, J Kelly, J Morgan, M Madden, F Shanahan

Department of Surgery and Medicine, National University of Ireland, Cork, Ireland.

BACKGROUND: Micrometastases within bone marrow have been shown to indicate a poor prognosis in patients with epithelial tumours. However, the degree to which micrometastases represent true residual disease or cell shedding and metastatic potential, is unclear. AIM: To explore whether micrometastases represent residual disease, bone marrow taken from carefully staged patients before and after (> 6 months) "curative" resection of a primary gastrointestinal cancer was studied prospectively. PATIENTS/METHODS: Seventy two consecutive patients were studied; the only exclusions were patients with known overt metastatic disease at the time of surgery. Micrometastatic cells were quantified per 10(5) marrow cells by flow cytometry after staining for contaminant cytokeratin-18 positive cells. RESULTS: Micrometastases were detected preoperatively in 22% (16/72) of all patients, comprising 11 (23%) of 48 with colorectal cancer, five (33%) of 15 with gastric adenocarcinoma and none (0%) of nine with oesophageal squamous cancer. Although fewer metastatic cells were detected in postoperative bone marrow, and clearance of marrow deposits was evident in most patients, the persistence of micrometastases in five of 16 patients after resection, without evidence of tumour recurrence, indicates a subset with true residual disease. Detection of micrometastases postoperatively (persistent or newly developed) was significantly associated with development of overt metastases during the subsequent 12-18 months of follow up (nine of 19 patients) when compared with patients testing negative for micrometastases (eight of 53; p < 0.01). CONCLUSIONS: Preoperative detection of micrometastases may reflect either transient shedding of cells, metastatic potential or residual disease, but postoperative micrometastases indicate minimal residual disease. Identification of these patients is important because they may benefit from adjuvant therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Micrometastases: are they clinically significant disease?

H J Andreyev and D Cunningham
Gut 1997 40: 555-556. [PDF]

This article has been cited by other articles:

• Wang, J.-Y., Lin, S.-R., Wu, D.-C., Lu, C.-Y., Yu, F.-J., Hsieh, J.-S., Cheng, T.-L., Koay, L.-B., Uen, Y.-H. (2007). Multiple Molecular Markers as Predictors of Colorectal Cancer in Patients with Normal Perioperative Serum Carcinoembryonic Antigen Levels. Clin. Cancer Res. 13: 2406-2413 [Abstract] [Full Text]  
• Setoyama, T., Natsugoe, S., Okumura, H., Matsumoto, M., Uchikado, Y., Ishigami, S., Owaki, T., Takao, S., Aikou, T. (2006). Carcinoembryonic antigen messenger RNA expression in blood predicts recurrence in esophageal cancer.. Clin. Cancer Res. 12: 5972-5977 [Abstract] [Full Text]  
• Lagarde, S. M., ten Kate, F. J.W., Reitsma, J. B., Busch, O. R.C., van Lanschot, J. J. B. (2006). Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction. JCO 24: 4347-4355 [Abstract] [Full Text]  
• Spence, G. M., Graham, A. N. J., Mulholland, K., Maxwell, P., McCluggage, W. G., Sloan, J. M., McGuigan, J. A. (2004). Bone Marrow Micrometastases and Markers of Angiogenesis in Esophageal Cancer. Ann. Thorac. Surg. 78: 1944-1949 [Abstract] [Full Text]  
• Partridge, M., Brakenhoff, R., Phillips, E., Ali, K., Francis, R., Hooper, R., Lavery, K., Brown, A., Langdon, J. (2003). Detection of Rare Disseminated Tumor Cells Identifies Head and Neck Cancer Patients at Risk of Treatment Failure. Clin. Cancer Res. 9: 5287-5294 [Abstract] [Full Text]  
• Redmond, K. C., Wang, J. H., Austin, K. K., Relihan, N., McGreal, G., Kirwan, W. O., Richardson, D., Kelly, J., Redmond, H. P., Braun, S., Harbeck, N., Pantel, K. (2001). Is Immunohistochemical Analysis an Appropriate Diagnostic Technique for Bone Marrow Micrometastases?. JCO 19: 3589-3592 [Full Text]  
• Tortola, S., Steinert, R., Hantschick, M., Peinado, M. A., Gastinger, I., Stosiek, P., Lippert, H., Schlegel, W., Reymond, M. A. (2001). Discordance Between K-ras Mutations in Bone Marrow Micrometastases and the Primary Tumor in Colorectal Cancer. JCO 19: 2837-2843 [Abstract] [Full Text]  
• Gerber, B., Krause, A., Muller, H., Richter, D., Reimer, T., Makovitzky, J., Herrnring, C., Jeschke, U., Kundt, G., Friese, K. (2001). Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation With Other Prognostic Factors. JCO 19: 960-971 [Abstract] [Full Text]  
• Maguire, D., O'Sullivan, G.C., McNamara, B., Collins, J.K., Shanahan, F. (2000). Bone-marrow micrometastases in patients with brain metastases from epithelial cell tumours. QJM 93: 611-615 [Abstract] [Full Text]  
• SHANAHAN, F., O'SULLIVAN, G.C., O'LEARY, C. (2000). Colorectal cancer: still a major killer despite progress on many fronts. QJM 93: 131-134 [Full Text]  
• Weckermann, D., Muller, P., Wawroschek, F., Krawczak, G., Riethmuller, G., Schlimok, G. (1999). Micrometastases of Bone Marrow in Localized Prostate Cancer: Correlation With Established Risk Factors. JCO 17: 3438-3443 [Abstract] [Full Text]